IMPACT OF PSORIATIC ARTHRITIS MANIFESTATIONS ON PERCEPTION OF PAIN IMPROVEMENT: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDIES WITH GUSELKUMAB

被引：0

作者：

Nash, P. ^{[1
,2
]}

Mcinnes, I. ^{[3
]}

Ritchlin, C. T. ^{[4
]}

Tam, L. S. ^{[5
]}

Soriano, E. ^{[6
]}

Starr, M. ^{[7
]}

Rampakakis, E. ^{[8
,9
]}

Lavie, F. ^{[10
]}

Shawi, M. ^{[11
]}

Baraliakos, X. ^{[12
,13
]}

Mease, P. J. ^{[14
,15
]}

机构：

[1] Griffith Univ, Maroochydore, Australia

[2] Univ Queensland, Rheumatol Res Unit, Maroochydore, Australia

[3] Univ Glasgow, Inst Infect Immun & Inflammat, Coll Med Vet & Life Sci, Glasgow, Scotland

[4] Univ Rochester, Dept Med Allergy Immunol & Rheumatol, Med Ctr, Rochester, NY USA

[5] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China

[6] Hosp Italiano Buenos Aires, Rheumatol, Buenos Aires, Argentina

[7] McGill Univ, Div Rheumatol, Hlth Ctr, Montreal, PQ, Canada

[8] McGill Univ, Dept Pediat, Montreal, PQ, Canada

[9] JSS Med Res Inc, Sci Affairs, Montreal, PQ, Canada

[10] Janssen Cilag Global Med Affairs, Immunol Global Med Affairs, Issy Les Moulineaux, France

[11] Janssen Pharmaceut Co Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA

[12] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany

[13] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[14] St Joseph Hlth, Seattle, WA USA

[15] Univ Washington, Rheumatol Res, Seattle, WA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

bDMARD; Pain; Psoriatic arthritis; BIOLOGIC-NAIVE; DOUBLE-BLIND;

D O I：

10.1136/annrheumdis-2023-eular.555

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB1095

引用

页码：1771 / 1772

页数：2

共 50 条

[21] Efficacy of guselkumab in bionaive psoriatic arthritis patients with severe disease activity: post hoc analysis of Phase 3, randomized, double-blind, placebo-controlled study
Ritchlin, Christopher T.
Lubrano, Ennio
Chimenti, Maria Sole
Leibowitz, Evan
Sharaf, Mohamed
Rampakakis, Emmanouil
Chakravarty, Soumya
Nantel, Francois
Lavie, Frederic
Deodhar, Atul
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[22] Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Selmi, Carlo
Salaffi, Fausto
Aydin, Sibel
Soriano, Enrique
Rampakakis, Emmanouil
Sharaf, Mohamed
Zimmermann, Miriam
Lavie, Frederic
Nash, Peter
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2809 - 2811
[23] Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Nash, Peter
Coates, Laura C.
Fleischmann, Roy
Papp, Kim A.
Jesus Gomez-Reino, Juan
Kanik, Keith S.
Wang, Cunshan
Wu, Joseph
Menon, Sujatha
Hendrikx, Thijs
Ports, William C.
RHEUMATOLOGY AND THERAPY, 2018, 5 (02) : 567 - 582
[24] Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Peter Nash
Laura C. Coates
Roy Fleischmann
Kim A. Papp
Juan Jesus Gomez-Reino
Keith S. Kanik
Cunshan Wang
Joseph Wu
Sujatha Menon
Thijs Hendrikx
William C. Ports
Rheumatology and Therapy, 2018, 5 : 567 - 582
[25] Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
Nash, Peter
Tam, Lai-Shan
Tsai, Wen-Chan
Leung, Ying-Ying
Furtner, Daniel
Sheng, Shihong
Wang, Yanli
Shawi, May
Kollmeier, Alexa
Sherlock, Jonathan
Cua, Daniel
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2769 - 2772
[26] Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
Ritchlin, Christopher T.
Mease, Philip J.
Boehncke, Wolf-Henning
Tesser, John
Schiopu, Elena
Chakravarty, Soumya D.
Kollmeier, Alexa P.
Xu, Xie L.
Shawi, May
Jiang, Yusang
Sheng, Shihong
Wang, Yanli
Xu, Stephen
Merola, Joseph F.
McInnes, Iain B.
Deodhar, Atul
RMD OPEN, 2022, 8 (01):
[27] Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Ritchlin, Christopher
Lubrano, Ennio
Chimenti, Maria Sole
Leibowitz, Evan
Sharaf, Mohamed
Adelakun, Oyediran
Rampakakis, Emmanouil
Nantel, Francois
Lavie, Frederic
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2999 - 3001
[28] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Coates, Laura C.
Rahman, Proton
Mease, Philip J.
Shawi, May
Rampakakis, Emmanouil
Kollmeier, Alexa P.
Xu, Xie L.
Chakravarty, Soumya D.
McInnes, Iain B.
Tam, Lai-Shan
BMC RHEUMATOLOGY, 2024, 8 (01)
[29] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Laura C. Coates
Proton Rahman
Philip J. Mease
May Shawi
Emmanouil Rampakakis
Alexa P. Kollmeier
Xie L. Xu
Soumya D. Chakravarty
Iain B. McInnes
Lai-Shan Tam
BMC Rheumatology, 8
[30] Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis
Schett, G.
Mease, P.
Kavanaugh, A.
Adebajo, A.
Gomez-Reino, J.
Wollenhaupt, J.
Cutolo, M.
Lespessailles, E.
Shah, K.
Hu, A.
Stevens, R.
Edwards, C.
Birbara, C.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 122 - 122

← 1 2 3 4 5 →